Harris Kaplan and Jun Huangpu led the Inflammatory/Autoimmune panel session at the Windhover Therapeutic Partnership Conference in Boston, selecting the top 10 “projects to watch” in the coming year in that therapeutic category. Kaplan told Windhover’s emerging medical ventures magazine Start-Up that the space is just beginning to blossom. The unmet need is vast, there are emerging opportunities in both small and large molecule therapies, and new targets and mechanisms of action can be combined with the need for second-generation and multiple-target drug cocktails. While several new pipeline candidates, such as small oral molecules, could drive treatments from specialists to primary care physicians, Kaplan expects that a high price awaits any licensed product that shows efficacy.
For more on emerging therapeutic categories, including the top ten projects, check out the November 2009 issue of Start-Up.